PharmaCyte Biotech (PMCB) Other Non-Current Liabilities (2015 - 2026)
PharmaCyte Biotech (PMCB) posted quarterly Other Non-Current Liabilities of $10.9 million for Q2 2026, up 2915.43% year-over-year from $363000.0 in Q2 2025, and down 26.01% quarter-over-quarter from $14.8 million in Q1 2026.
PharmaCyte Biotech (PMCB) Other Non-Current Liabilities (2015 - 2026) Analysis & Trends
PharmaCyte Biotech (PMCB) has reported Other Non-Current Liabilities for 5 consecutive years, with $10.9 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Other Non-Current Liabilities rose 2915.43% year-over-year to $10.9 million; the TTM figure through Apr 2026 stood at $10.9 million (up 2915.43% YoY), while the FY2026 annual figure was $10.9 million, up 2915.43% from the prior year.
- Other Non-Current Liabilities declined to $10.9 million in Q2 2026 per PMCB's latest filing, from $14.8 million in the prior quarter.
- Across five years, Other Non-Current Liabilities topped out at $16.2 million in Q4 2025 and bottomed at $363000.0 in Q2 2025.
- Historically, Other Non-Current Liabilities has averaged $9.8 million across 4 years, with a median of $10.9 million in 2024.
- Annual changes were most pronounced in 2025 — Other Non-Current Liabilities tumbled 96.63% — and 2026, when it surged 2915.43%.
- PharmaCyte Biotech's Other Non-Current Liabilities stood at $15.6 million in 2023, then slumped by 55.88% to $6.9 million in 2024, then jumped by 135.07% to $16.2 million in 2025, then plunged by 32.23% to $10.9 million in 2026.
- Business Quant data shows PMCB's Other Non-Current Liabilities at $10.9 million in Q2 2026, $14.8 million in Q1 2026, and $16.2 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | PharmaCyte Biotech | 4.38 Mn | 4.38 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | 10.95 Mn |
| Jan 31, 2026 | 14.79 Mn |
| Oct 31, 2025 | 16.15 Mn |
| Jul 31, 2025 | 458,000.00 |
| Apr 30, 2025 | 363,000.00 |
| Jan 31, 2025 | 2.38 Mn |
| Oct 31, 2024 | 6.87 Mn |
| Jul 31, 2024 | 8.70 Mn |
| Apr 30, 2024 | 10.78 Mn |
| Jan 31, 2024 | 14.93 Mn |
| Oct 31, 2023 | 15.57 Mn |
| Jul 31, 2023 | 15.58 Mn |
| Oct 31, 2015 | 29,746.00 |
| Apr 30, 2015 | 492,049.00 |